Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Bruzzi

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|June 8, 2007
Adjuvant mitotane treatment for adrenocortical carcinomaMassimo Terzolo, Alberto Angeli, Martin Fassnacht, et al.
JAMA|June 18, 2009
Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of colorectal cancerDaniele Regge, Cristiana Laudi, Giovanni Galatola, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
Frontiers in Oncology|August 14, 2023
U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenarioSergio Bracarda, Roberto Iacovelli, Valentina Baldazzi, et al.
Infectious Diseases and Therapy|July 30, 2021
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)Matteo Bassetti, Daniele Roberto Giacobbe, Paolo Bruzzi, et al.
Orphanet Journal of Rare Diseases|November 27, 2014
TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complexJohn C Kingswood, Paolo Bruzzi, Paolo Curatolo, et al.
The Lancet. Oncology|May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialAlessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2020
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma GroupsAlessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Scientific Reports|October 28, 2017
Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL PathwayCecilia Marini, Silvia Bruno, Francesco Fiz, et al.
Cancer|October 13, 2021
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trialSandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|June 8, 2007
Adjuvant mitotane treatment for adrenocortical carcinomaMassimo Terzolo, Alberto Angeli, Martin Fassnacht, et al.
JAMA|June 18, 2009
Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of colorectal cancerDaniele Regge, Cristiana Laudi, Giovanni Galatola, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
Frontiers in Oncology|August 14, 2023
U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenarioSergio Bracarda, Roberto Iacovelli, Valentina Baldazzi, et al.
Infectious Diseases and Therapy|July 30, 2021
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)Matteo Bassetti, Daniele Roberto Giacobbe, Paolo Bruzzi, et al.
Orphanet Journal of Rare Diseases|November 27, 2014
TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complexJohn C Kingswood, Paolo Bruzzi, Paolo Curatolo, et al.
The Lancet. Oncology|May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialAlessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2020
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma GroupsAlessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Scientific Reports|October 28, 2017
Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL PathwayCecilia Marini, Silvia Bruno, Francesco Fiz, et al.
Cancer|October 13, 2021
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trialSandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Pageof 16